HANGZHOU, China I January 10, 2025 I Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily. SAN DIEGO, CA, USA I January 8, 2025 I Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), ...

Drugs for metabolic diseases, vaccines, and cancer therapies feature among new product launches this year that could top $1 billion in annual sales or be clinical "game changers" in the next five ...

A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes ...

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the ...

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

The firm's endorsement follows Structure Therapeutics' expansion of its drug pipeline with ACCG-2671, a once-daily small molecule amylin agonist. According to InvestingPro data, analyst targets for ...

CagriSema is a weekly injection combining semaglutide, which is the active ingredient in Wegovy and mimics the gut hormone GLP-1, and a separate molecule called cagrilintide that mimics the pancreatic ...